4,764 reports of this reaction
2.9% of all FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE reports
#5 most reported adverse reaction
PNEUMONIA is the #5 most commonly reported adverse reaction for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, manufactured by GlaxoSmithKline LLC. There are 4,764 FDA adverse event reports linking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE to PNEUMONIA. This represents approximately 2.9% of all 162,228 adverse event reports for this drug.
Patients taking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE who experience pneumonia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PNEUMONIA is a less commonly reported adverse event for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, but still significant enough to appear in the safety profile.
In addition to pneumonia, the following adverse reactions have been reported for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE:
The following drugs have also been linked to pneumonia in FDA adverse event reports:
PNEUMONIA has been reported as an adverse event in 4,764 FDA reports for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
PNEUMONIA accounts for approximately 2.9% of all adverse event reports for FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, making it a notable side effect.
If you experience pneumonia while taking FLUTICASONE PROPIONATE AND SALMETEROL XINAFOATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.